Volume 92, Issue 4 pp. 750-751
Peripheral Vascular Disease

Waiting for Godot: Anticipating answers on embolic protection unlikely to arrive

Khalil Anouti MD

Corresponding Author

Khalil Anouti MD

Division of Cardiovascular Disease, Lankenau Medical Center and Lankenau Institute for Medical Research, Wynnewood, Pennsylvania

Correspondence

Khalil Anouti, MD, Lankenau Medical Center, 100 E. Lancaster Avenue, 356 Medical Office Building East, Wynnewood, PA 19096, USA.

Email: [email protected]

Search for more papers by this author
William A. Gray MD

William A. Gray MD

Division of Cardiovascular Disease, Lankenau Medical Center and Lankenau Institute for Medical Research, Wynnewood, Pennsylvania

Search for more papers by this author
First published: 19 October 2018
Citations: 2

Key Points

  • For symptomatic and asymptomatic patient with high or intermediate risk of CEA complications, CAS with the use of EPDs has a very low rate of in-hospital stroke and death
  • There is no statistically significant difference in ipsilateral stroke/TIA and any stroke/TIA between the different device platforms
  • Further efforts to assess differences between EPD devices would likely need to involve a surrogate endpoint due to the very low rates of clinical events

CONFLICT OF INTEREST

Nothing to report.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.